The Office of the pan-Canadian Pharmaceutical Alliance (pCPA) assesses brand name drug products for public funding either collectively or individually at the provincial and territorial levels. Each month the pCPA issues an update on the previous month’s negotiation activity. A file is complete once a Letter of Intent (LOI) is signed, a decision has been made not to negotiate, or an agreement is not reached. Below you will find an overview of the new pCPA activity along with PDCI’s insights into new developments for your interest. Find more details at http://bit.ly/pCPANews

To find out more information about pCPA negotiations and how PDCI’s reimbursement strategy team can help navigate through pCPA discussions, please contact John-Paul Dowson at jp.dowson@pdci.ca